Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: Induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis

Cancer Research

Volumn 62, Issue 23, 2002, Pages 6901-6908

  Gaedicke, Simone ^a   Firat Geier, Elke ^a   Constantiniu, Oana ^a   Lucchiari Hartz, Maria ^a   Freudenberg, Marina ^a   Galanos, Chris ^a   Niedermann, Gabriele ^a  

^a MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID; CHYMOTRYPSIN; CYCLIN DEPENDENT KINASE INHIBITOR; PEPTIDE; POLYUBIQUITIN; PROTEIN P21; PROTEIN P53; PROTEINASE INHIBITOR; PROTEOME; RITONAVIR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CELL CYCLE; CELL LINE; CELL LYSATE; CELL PROLIFERATION; CELL STRAIN; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SOLUBILITY; THYMOMA; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TRANSFORMED; CYSTEINE ENDOPEPTIDASES; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; MULTIENZYME COMPLEXES; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; RITONAVIR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036896223     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Danner, S. A., Carr, A., Leonard, J. M., Lehman, L. M., Gudiol, F., Gonzales, J., Raventos, A., Rubio, R., Bouza, E., Pintado, V., et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N. Engl. J. Med., 333: 1528-1533, 1995.
2. Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., La Marca, A., Leonard, J. M., et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med., 333: 1534-1539, 1995.
3. Ullum, H., Katzenstein, T., Aladdin, H., Nielsen, C., Sondergaard, S. R., Gerstoft, J., Skinhoj, P., and Pedersen, B. K. Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment. Scand. J. Immunol., 49: 539-547, 1999.
4. Kempf, D. J., Marsh, K. C., Denissen, J. F., McDonald, E., Vasavanonda, S., Flentge, C. A., Green, B. E., Fino, L., Park, C. H., Kong, X. P., et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA, 92: 2484-2488, 1995.
5. Andre, P., Groettrup, M., Klenerman, P., de Giuli, R., Booth, B. L., Jr., Cerundolo, V., Bonneville, M., Jotereau, F., Zinkernagel, R. M., and Lotteau, V. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA, 95: 13120-13124, 1998.
6. Ciechanover, A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J., 17: 7151-7160, 1998.
7. Chen, Z. J., and Maniatis, T. Role of the ubiquitin-proteasome pathway in NF-κB activation, In: J. M. Peters, J. R. Harris, and D. Finley (eds.), Ubiquitin and the Biology of the Cell, pp. 303-321. London: Plenum Press, 1998.
8. Koepp, D. M., Harper, J. W., and Elledge, S. J. How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell. 97: 431-434, 1999.
9. Orlowski, R. Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ., 6: 303-313, 1999.
10. Grimm, L. M., and Osborne, B. A. Apoptosis and the proteasome. Results Probl. Cell Differ., 23: 209-228, 1999.
11. Ping Dou, Q., and Li, B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist. Updates, 2: 215-223, 1999.
12. Omura, S., Matsuzaki, K., Fujimoto, T., Kosuge, K., Furuya, T., Fujita, S., and Nakagawa, A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J. Antibiot. (Tokyo), 44: 117-118, 1991.
13. Grimm, L. M., Goldberg, A. L., Poirier, G. G., Schwartz, L. M., and Osborne, B. A. Proteasomes play an essential role in thymocyte apoptosis. EMBO J., 15: 3835-3844, 1996.
14. Sadoul, R., Fernandez, P. A., Quiquerez, A. L., Martinou, I., Maki, M., Schroter, M., Becherer, J. D., Irmler, M., Tschopp, J., and Martinou, J. C. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J., 15: 3845-3852, 1996.
15. Orlowski, R. Z., Eswara, J. R., Lafond-Walker, A., Grever, M. R., Orlowski, M., and Dang, C. V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res., 58: 4342-4348. 1998.
16. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res., 59: 2615-2622, 1999.
17. Sun, J., Nam, S., Lee, C. S., Li, B., Coppola, D., Hamilton, A. D., Dou, Q. P., and Sebti, S. M. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res., 61: 1280-1284, 2001.
18. Freudenberg, M. A., Keppler, D., and Galanos, C. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect. Immun., 51: 891-895, 1986.
19. Kyriazis, A. P., Kyriazis, A. A., Scarpelli, D. G., Fogh, J., Rao, M. S., and Lepera, R. Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: Morphologic, biologic, and biochemical characteristics. Am. J. Pathol., 106: 250-260, 1982.
20. Geier, E., Pfeifer, G., Wilm, M., Lucchiari-Hartz, M., Baumeister, W., Eichmann, K., and Niedermann, G. A giant protease with potential to substitute for some functions of the proteasome. Science (Wash. DC), 283: 978-981, 1999.
21. Fenteany, G. Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., and Schreiber, S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (Wash. DC), 268: 726-731, 1995.
22. Tsubuki, S., Kawasaki, H., Saito, Y., Miyashita, N., Inomata, M., and Kawashima, S. Purification and characterization of a Z-Leu-Leu-Leu-AMC degrading protease expected to regulate neurite formation: A novel catalytic activity in proteasome. Biochem. Biophys. Res. Commun., 196: 1195-1201, 1993.
23. Dick, L. R., Cruikshank, A. A., Destree, A. T., Grenier, L., McCormack, T. A., Melandri, F. D., Nunes, S. L., Palombella, V. J., Parent, L. A., Plamondon, L., and Stein, R. L. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem., 272: 182-188, 1997.
24. Maki, C. G., Huibregtse, J. M., and Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res., 56: 2649-2654, 1996.
25. Gottlieb, T. M., and Oren, M. p53 and apoptosis. Semin. Cancer Biol., 8: 359-368, 1998.
26. Eliyahu, D., Goldfinger, N., Pinhasi-Kimhi, O., Shaulsky, G., Skurnik, Y., Arai, N., Rotter, V., and Oren, M. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene, 3: 313-321, 1988.
27. Yamato, K., Yamamoto, M., Hirano, Y., and Tsuchida, N. A human temperature-sensitive p53 mutant p53Val-138: Modulation of the cell cycle, viability and expression of p53-responsive genes. Oncogene, 11: 1-6, 1995.
28. Wolf, D., and Rotter, V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc. Natl. Acad. Sci. USA, 82: 790-794, 1985.
29. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991.
30. Schmidtke, G., Holzhutter, H. G., Bogyo, M., Kairies, N., Groll, M., de Giuli, R., Emch, S., and Groettrup, M. How an inhibitor of the HIV-1 protease modulates proteasome activity. J. Biol. Chem., 274: 35734-35740, 1999.
31. Sekiguchi, T., and Hunter, T. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells. Oncogene, 16: 369-380, 1998.
32. Schmidtke, G., Emch, S., Groettrup, M., and Holzhutter, H. G. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20S proteasome. J. Biol. Chem., 275: 22056-22063, 2000.
33. Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M., and Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol., 18: 538-543, 2000.
34. Liang, J. S., Distler, O., Cooper, D. A., Jamil, H., Deckelbaum, R. J., Ginsberg, H. N., and Sturley, S. L. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med., 7: 1327-1331, 2001.
35. Tanahashi, N., Murakami, Y., Minami, Y., Shimbara, N., Hendil, K. B., and Tanaka, K. Hybrid proteasomes. Induction by interferon-γ and contribution to ATP-dependent proteolysis. J. Biol. Chem., 275: 14336-14345, 2000.
36. Sheaff, R. J., Singer, J. D., Swanger, J., Smitherman, M., Roberts, J. M., and Clurman, B. E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell, 5: 403-410, 2000.
37. Touitou, R., Richardson, J., Bose, S., Nakanishi, M., Rivett, J., and Allday, M. J. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8α-subunit of the 20S proteasome. EMBO J., 20: 2367-2375, 2001.
38. Rousset, R., Desbois, C., Bantignies, F., and Jalinot, P. Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome. Nature (Lond.), 381: 328-331, 1996.
39. Kroll, M., Conconi, M., Desterro, M. J., Marin, A., Thomas, D., Friguet, B., Hay, R. T., Virelizier, J. L., Arenzana-Seisdedos, F., and Rodriguez, M. S. The carboxyterminus of IκBα determines susceptibility to degradation by the catalytic core of the proteasome. Oncogene, 15: 1841-1850, 1997.
40. Pati, S., Pelser, C. B., Dufraine, J., Bryant, J. L., Reitz, M. S., Jr., and Weichold, F. F. Antitumorigenic effects of HIV protease inhibitor ritonavir: Inhibition of Kaposi sarcoma. Blood, 99: 3771-3779, 2002.
41. Verma, R., and Deshaies, R. J. A proteasome howdunit: The case of the missing signal. Cell, 101: 341-344, 2000.
42. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
43. Harrington, E. A., Fanidi, A., and Evan, G. I. Oncogenes and cell death. Curr. Opin. Genet. Dev., 4: 120-129, 1994.
44. Glas, R., Bogyo, M., McMaster, J. S., Gaczynska, M., and Ploegh, H. L. A proteolytic system that compensates for loss of proteasome function. Nature (Lond.), 392: 618-622, 1998.
45. Norvir, Ritonavir Product Monograph. North Chicago, IL: Abbott Laboratories, 1997.
46. Gatti, G., Di Biagio, A., Casazza, R., De Pascalis, C., Bassetti, M., Cruciani, M., Vella, S., and Bassetti, D. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring. AIDS, 13: 2083-2089, 1999.
47. Molla, A., Vasavanonda, S., Kumar, G., Sham, H. L., Johnson, M., Grabowski, B., Denissen, J. F., Kohlbrenner, W., Plattner, J. J., Leonard, J. M., Norbeck, D. W., and Kempf, D. J. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology, 250: 255-262, 1998.
48. Sgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S., Palladino, C., Leone, P., Bugarini, R., Malavasi, L., Cafaro, A., Falchi, M., Valdembri, D., Rezza, G., Bussolino, F., Monini, P., and Ensoli, B. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med., 8: 225-232, 2002.
49. Burdick, A. E., Carmichael, C., Rady, P. L., Tyring, S. K., and Badiavas, E. Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy. J. Am. Acad. Dermatol., 37: 648-649, 1997.
50. Diz Dios, P., Ocampo Hermida, A., Miralles Alvarez, C., Vazquez Garcia, E., and Martinez Vazquez, C. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy. Oral Oncol., 34: 236-238, 1998.